Aduhelm Approval Boosts Other Alzheimer’s Drug Developers
Even Companies Not Focused On Clearing Amyloid Benefitted
Executive Summary
Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.
You may also be interested in...
Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.